Who
Jerome B. Zeldis
Director
Company insider
Files Form 4 as: Director, Soligenix; Director, PTC Therapeutics; Director, NexGel; Executive VP of Research & Dev, NexImmune; Director, Streamex; Officer, Sorrento Therapeutics; Director, MetaStat; Director, Alliqua BioMedical.
In numbers
- Trades disclosed
- 131
- Buys
- 19
- Sells
- 3
- Bought
- $553K
- Sold
- $2.0M
- Companies
- 9
- Companies where not an officer
- 7
- First trade
- 31 Mar 2008
- Last trade
- 12 Oct 2026
- Last filed
- 13 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 12 Oct 2026filed 13 Oct 2026 | SNGX Soligenixoption or derivative · Biotechnology | SEC FORM 4 Code D | —54 at $0.00 | filing |
| 12 Oct 2026filed 13 Oct 2026 | SNGX Soligenixoption or derivative · Biotechnology | SEC FORM 4 Code D | —74 at $0.00 | filing |
| 12 Oct 2026filed 13 Oct 2026 | SNGX Soligenixoption or derivative · Biotechnology | SEC FORM 4 Code D | —128 at $0.00 | filing |
| 12 Oct 2026filed 13 Oct 2026 | SNGX Soligenixoption or derivative · Biotechnology | SEC FORM 4 Code D | —63 at $0.00 | filing |
| 12 Oct 2026filed 13 Oct 2026 | SNGX Soligenixoption or derivative · Biotechnology | SEC FORM 4 Code D | —121 at $0.00 | filing |
| 12 Oct 2026filed 13 Oct 2026 | SNGX Soligenixoption or derivative · Biotechnology | SEC FORM 4 Code D | —192 at $0.00 | filing |
| 17 Sep 2026filed 18 Sep 2026 | SNGX Soligenixoption or derivative · Biotechnology | SEC FORM 4 Code A | —78,947 at $0.00 | filing |
| 17 Sep 2026filed 18 Sep 2026 | SNGX Soligenixoption or derivative · Biotechnology | SEC FORM 4 Code A | —78,947 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | PTCT PTC TherapeuticsBiotechnology | SEC FORM 4 Code A | —4,000 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | PTCT PTC Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —3,475 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | PTCT PTC Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —3,475 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | PTCT PTC TherapeuticsBiotechnology | SEC FORM 4 Code A | —4,000 at $0.00 | filing |
| 25 Jun 2025filed 27 Jun 2025 | NXGL NexGeloption or derivative · Medical Devices | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 20 Jun 2025filed 20 Jun 2025 | SNGX Soligenixoption or derivative · Biotechnology | SEC FORM 4 Code A | —17,647 at $0.00 | filing |
| 3 Jan 2025filed 7 Jan 2025 | PTCT PTC Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —8,800 at $0.00 | filing |
| 3 Jan 2025filed 7 Jan 2025 | PTCT PTC TherapeuticsBiotechnology | SEC FORM 4 Code A | —4,000 at $0.00 | filing |
| 12 Dec 2024filed 13 Dec 2024 | SNGX Soligenixoption or derivative · Biotechnology | SEC FORM 4 Code A | —8,646 at $0.00 | filing |
| 2 Dec 2024filed 4 Dec 2024 | PTCT PTC Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —12,000 at $0.00 | filing |
| 2 Dec 2024filed 4 Dec 2024 | PTCT PTC Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —12,000 at $0.00 | filing |
| 2 Dec 2024filed 4 Dec 2024 | PTCT PTC TherapeuticsBiotechnology | SEC FORM 4 Code M | $612K12,000 at $51.00 | filing |
News
Streamex Corp. Announces September 2026 Yield Dividend Distribution for GLDYSTEX · manilatimes.net · 19 Oct 2026PTC Therapeutics (NASDAQ:PTCT) & Aktis Oncology (NASDAQ:AKTS) Head to Head ContrastPTCT · dailypolitical.com · 19 Oct 2026Reviewing Soligenix (NASDAQ:SNGX) and Curis (NASDAQ:CRIS)SNGX · themarketsdaily.com · 17 Oct 2026PTC Therapeutics (NASDAQ:PTCT) Director Michael Schmertzler Sells 2,500 Shares of Company StockPTCT · tickerreport.com · 16 Oct 2026PTC Therapeutics (NASDAQ:PTCT) Stock: Insider Mark Elliott Boulding Sells 1,638 SharesPTCT · themarketsdaily.com · 9 Oct 2026NexGel (NASDAQ:NXGL) Shares Scheduled to Reverse Split on Monday, October 12thNXGL · themarketsdaily.com · 9 Oct 2026
0 headlines in the last 90 days name Jerome B. Zeldis; 6 articles from the last 14 days about the 4 companies they traded most, at most three about any one of them.